Literature DB >> 8452664

Immunological adverse effects of anticonvulsants. What is their clinical relevance?

F De Ponti1, S Lecchini, M Cosentino, C M Castelletti, A Malesci, G M Frigo.   

Abstract

Long term administration of anticonvulsants is sometimes associated with impairment of the humoral and/or cellular immune response. Furthermore, certain well known adverse reactions to antiepileptics may have an immunotoxicological origin e.g. lymphadenopathy, pseudolymphoma and systemic lupus erythematosus. However, two important questions remain unresolved. First, the possibility that epilepsy per se might be primarily associated with immune alterations makes it difficult to assess the pathogenetic role of a specific drug, especially in a patient population usually on multiple drug therapy. Secondly, the clinical relevance of some of the observed immunological abnormalities is still highly controversial. This review is intended to give an outline of the present state of knowledge on the effects of anticonvulsants on humoral, cellular and nonspecific immunity, with particular regard to some of the major clinical conditions that have been ascribed to drug-induced immune dysregulation, such as pseudolymphoma and systemic autoimmune diseases. The immunotoxic potential of anticonvulsants appears to be low, and immunological monitoring is not usually required except in patients with known immune defects.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8452664     DOI: 10.2165/00002018-199308030-00005

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  173 in total

1.  Phenytoin-induced depression of salivary IgA.

Authors:  J A Aarli
Journal:  Acta Otolaryngol       Date:  1976 Sep-Oct       Impact factor: 1.494

Review 2.  Cutaneous and immunologic reactions to phenytoin.

Authors:  A K Silverman; J Fairley; R C Wong
Journal:  J Am Acad Dermatol       Date:  1988-04       Impact factor: 11.527

3.  Phenytoin-carbamazepine cross-sensitivity.

Authors:  S B Reents; W E Luginbuhl; S M Davis
Journal:  DICP       Date:  1989-03

4.  Assessment of polymorphonucleate leucocyte functions in adult epileptic patients undergoing long-term phenytoin treatment.

Authors:  G Ricevuti; M Marcoli; G Gatti; A Mazzone; S Lecchini; G M Frigo
Journal:  Hum Toxicol       Date:  1986-07

5.  An unusual dual hypersensitivity reaction induced by diphenylhydantoin.

Authors:  T S Sisca
Journal:  Am J Hosp Pharm       Date:  1973-05

6.  Pseudolymphoma induced by diphenylhydantoin.

Authors:  P Choovivathanavanich; E M Wallace; P R Scaglione
Journal:  J Pediatr       Date:  1970-04       Impact factor: 4.406

7.  Antinuclear antibodies and lupus-like syndromes in children receiving anticonvulsants.

Authors:  B H Singsen; L Fishman; V Hanson
Journal:  Pediatrics       Date:  1976-04       Impact factor: 7.124

8.  Depression of immune competence by phenytoin and carbamazepine. Studies in vivo and in vitro.

Authors:  T C Sorrell; I J Forbes
Journal:  Clin Exp Immunol       Date:  1975-05       Impact factor: 4.330

9.  Immunological studies on delayed hypersensitivity to phenytoin--II. The delayed skin reaction induced by BSA-phenytoin conjugate.

Authors:  K Taska; M Uokawa; H Miyake; C Kamei
Journal:  Int J Immunopharmacol       Date:  1987

10.  Erythroderma, hypogammaglobulinemia, and T-cell lymphocytosis. Occurrence following therapy with phenytoin.

Authors:  M A Lillie; L C Yang; P J Honig; C S August
Journal:  Arch Dermatol       Date:  1983-05
View more
  2 in total

1.  Neurological autoantibodies in drug-resistant epilepsy of unknown cause.

Authors:  Mehmet Tecellioglu; Ozden Kamisli; Suat Kamisli; Fatma Ebru Yucel; Cemal Ozcan
Journal:  Ir J Med Sci       Date:  2018-03-09       Impact factor: 1.568

2.  Anticonvulsant-induced suppression of IFN-gamma production by lymphocytes obtained from cervical lymph nodes in glioma-bearing mice.

Authors:  M Yamada; M Ohkawa; K Tamura; E Mabuchi; H Kishima; M Tamura; K Shimizu
Journal:  J Neurooncol       Date:  2000-04       Impact factor: 4.130

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.